期刊文献+

计算机辅助药物分子设计在抗糖尿病PPARs调节剂方面的应用及研究进展 被引量:1

Application and progress in computer-aid drug design on ppars regulator
原文传递
导出
摘要 过氧化物酶体增殖激活受体是一类与调节体内糖脂代谢,改善胰岛素抵抗密切相关的受体。而计算机辅助药物分子设计越来越成为新药开发领域重要的研究热点,它的发展和应用,大大提高了药物设计和新药开发的效率。本文将对计算机辅助药物分子设计在抗糖尿病PPARs调节剂方面的应用及研究进展加以综述。 Peroxisome proliferator-activated receptors are a series of receptors related to metabolism of sugar and lipid and amelioration of insulin resistance. On the other hand, Computer-aid drug design has become the hot spot in the research of new drug design. Its appearance and development has greatly improvd the efficiency of development of new drug. Application and progress in Computer-aid Drug Design on PPARs regulators are summarized in this article.
出处 《武警后勤学院学报(医学版)》 CAS 2014年第1期73-79,共7页 Journal of Logistics University of PAP(Medical Sciences)
关键词 PPARs调节剂 计算机辅助药物分子设计 糖尿病 PPARs regulator Computer-aid drug design Diabetes
  • 相关文献

参考文献35

  • 1Michalik L,Wahli W.Peroxisome proliferator-activatedreceptors:three isotypes for a multitude of functions[J].CurrOpin Bioteohnol,1999,10(6):564-570.
  • 2徐成,王莉莉,刘洪英,覃丹,曹颖林,李松.新型PPARα/γ双重激动剂C618H抗2型糖尿病的实验研究[J].中国新药杂志,2007,16(6):450-454. 被引量:4
  • 3Shen JH,Xu XY,Cheng F,et al.Virtual screening on naturalproducts for discovering active compounds and target clues[J].Curr Med Chem,2003,10(21):2327-2342.
  • 4罗小民,蒋华良,沈建华,陈凯先.药物分子设计研究进展[J].中国科学院院刊,2003,18(4):255-259. 被引量:14
  • 5Staels B,Dallongeville J,Auwerx J,et al.Mechanism ofaction fibrate on lipid and lipoprotein metabolism[J].Circulation,1998,98(19):2088-2093.
  • 6杨彦博,周辛波,李松.PPARδ激动剂研究进展[J].国际药学研究杂志,2007,34(5):327-331. 被引量:3
  • 7Wang D,Wang H,Shi Q,et al.Prostaglandin E(2)promotescolorectal adenoms growth via transactivation of the nuclearperoxisome proliferator-activated receptor 8[J].Cancer Cell,2004,6(3):285-295.
  • 8Berger JP,Akiyama TE,Meinke PT.PPARs:therapeutictargets for metabolic disease[J].Trends Pharmacol Soi,2005,26(5):244-251.
  • 9BergerJ,Moller DE.The mechanisms of action of PPARs[J].Annu Rev Med,2002,53:409-435.
  • 10张新歌,李朝兴,张慧杰,汤宇,王瑱.选择性PPARγ调节剂治疗2型糖尿病的研究[J].药学进展,2005,29(12):550-556. 被引量:3

二级参考文献125

  • 1Li-hongLIU Xiao-kuiWANG Yuan-dongHU Jian-leiKANG Li-liWANG SongLI.Effects of a fatty acid synthase inhibitor on adipocyte differentiation of mouse 3T3-L1 cells[J].Acta Pharmacologica Sinica,2004,25(8):1052-1057. 被引量:7
  • 2陈娜,吴英良.PPARδ的结构及其生物学功能与疾病[J].中国药理学通报,2006,22(9):1035-1038. 被引量:11
  • 3[1]Nolte RT, Wisely GB, Westin S. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ [J]. Nature, 1998,395:137-143.
  • 4[2]Oberfield JL, Collins JL, Holmes CP. A peroxisome proliferator-activated receptor-γ ligand inhibits adipocyte differentiation [J]. Proc Natl Acad Sci USA, 1999,96:6102-6106.
  • 5[3]Willson TM, Cobb JE, Cowan DJ. The Structure-activity relationship between peroxisome proliferator-activated receptor-γ agonism and the antihyperglycemic activity of thiazolidinediones [J]. J Med Chem, 1996,39:665-668.
  • 6[4]Willson TM, Brown PJ, Sternbach DD. The PPARs: from orphan receptors to drug discovery [J]. J Med Chem, 2000,43(4):527-549.
  • 7[5]Raghavan K, Buolamwini JK,Fesen MR. Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: A comparative molecular field analysis (CoMFA) [J]. J Med Chem, 1995,38:890-897.
  • 8[6]Kurogi Y. Three-dimensional quantitative structure-activity relationships (3D-QSAR) of antidiabetic thiazolidinediones [J]. Drug Design Discov, 1999,16:109-118.
  • 9[7]Henke BR, Blanchard SG, Brackeen MF. N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents [J]. J Med Chem, 1998,41(25):5020-5036.
  • 10[8]Collins JL, Blanchard SG, Evan BG. N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety [J]. J Med Chem, 1998,41(25):5037-5054.

共引文献71

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部